Market Overview

UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Eli Lilly & Co.

Related LLY
Pharma M&A Frenzy Pushing These ETFs Higher - ETF News And Commentary
Stock Market News for April 23, 2014 - Market News
Pharma Deal Frenzy: A Bid to Boost Profits, Cut Risk (Fox Business)

In a report published Wednesday, Bank of America Merrill Lynch reiterated its Buy rating on Eli Lilly & Co. (NYSE: LLY), and raised its price target from $57.00 to $60.00.

BofA Merrill Lynch noted, “LLY offers a good mix of compelling valuation, an attractive dividend yield with a track record of returning cash to shareholders, and pipeline optionality. Several promising late-stage pipeline assets are underappreciated, in our view, and could be transformative to LLYs growth trajectory (ramucirumab, solanezumab and the four Phase III diabetes assets - two basal insulins, empagliflozin and dulaglutide).”

Eli Lilly & Co. closed on Tuesday at $51.88.

Posted-In: Bank of America Merrill LynchAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (LLY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free